<SEC-DOCUMENT>0001558370-23-008953.txt : 20230510
<SEC-HEADER>0001558370-23-008953.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510062536
ACCESSION NUMBER:		0001558370-23-008953
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230510
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		23904218

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20230510x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/10/2023 10:18:03 AM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: 4e80770a-7073-4b5b-8eaa-fea19eec320c -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20230510" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityCentralIndexKey" id="Tc_51Z7Tx_vFUW1pZuosJDL-w_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:AmendmentFlag" id="Tc_NbsMITndokKPDD3nzkBKGg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20230510.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-10</xbrli:startDate><xbrli:endDate>2023-05-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0e9ca0c2_ebd9_4bd2_825b_93ebacf24761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:DocumentType" id="Narr_Umhr-8V7EUS155CB_EeG2w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_qvhVZlugAEu2uqv3hRDAEA"><b style="font-weight:bold;">May&#160;10, 2023</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityRegistrantName" id="Narr_J0KFKz5yNESsTltE7q7WjA"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_xOn_q6r08kSeWAZGmHf_3g_2_0"></a><a id="Tc_8leinMhgWEC9qlMl-FB9UQ_2_2"></a><a id="Tc_RU5dwOIOW0a-iikYXBovFg_2_4"></a><a id="Tc_6dIo9YYwZUGgOGtAFFD9ow_6_0"></a><a id="Tc_uuKEZkJ_00GXNFFxQVhCbg_7_0"></a><a id="Tc_Uo3qnYkYjEqXaBLW7YSwZA_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_6syoK3mXA0KLPwtgHn-VwA_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityFileNumber" id="Tc_R2KzHtJ0ykKecPFIsPhIyA_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityTaxIdentificationNumber" id="Tc_8q0YhGrLREm2jPzp2BA5Qg_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityAddressAddressLine1" id="Tc_qCreB7x6XUGTyDg3vSOI6Q_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityAddressAddressLine2" id="Tc_MkBngZ3O-kWclAdz8e1NMw_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityAddressCityOrTown" id="Narr_64LjIYpPBkGZyBRZOA6fGw"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityAddressStateOrProvince" id="Narr_Z_NYv0CilEaCddyJryq9bQ"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:EntityAddressPostalZipCode" id="Tc_dlRLqiCO3UCsHBp-pnkwWA_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:CityAreaCode" id="Narr_ylZ6-Xmtd0ugBU5ywMHSmg"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:LocalPhoneNumber" id="Narr_JjM93AW0GEOgTNW4AcWxvg"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_Mt4HiR-DoUmxn3EUz-a1og"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_VlUf7qNlfU-hZmvZwmHH2g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_ry6IU21oP0utXATPzFW4gA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_n4QYc1-AR0WwqNO1qBpVtw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_FC0p88izn0uLzE4UntY5zA_1_0"></a><a id="Tc_rBZwRJ-ra0SIjHGD4mAk7w_1_1"></a><a id="Tc_8LYigIcJyEOU7Qb8tMhLRg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:Security12bTitle" id="Tc_L_t2sNxTCEi-OVboTCla7w_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" name="dei:TradingSymbol" id="Tc_Rl35CkyOoUSFsAPXjCRR-Q_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_Bukrt2ZW50SdEPcWo3D54g_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr__oUd76jhxk6t1IBHLOwvbw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;8.01</b></span>Other Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;10, 2023, Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, the Company&#8217;s development and commercialization partner, issued a press release announcing that the U.S.&#160;Food and Drug Administration (FDA) has approved ELFABRIO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease. A copy of the press release is attached hereto as Exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;9.01</b></span>Financial Statements and Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230510xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated May&#160;10, 2023</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;10, 2023</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20230510xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/10/2023 10:18:02 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:48.2pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="position:relative;vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:39pt;margin-left:2.0pt;margin-right:9pt;width:128pt;z-index:-9223372036603115520;"><div style="height:38.5pt;left:0pt;padding-bottom:0.5pt;position:relative;width:128pt;"><img src="plx-20230510xex99d1003.jpg" alt="Graphic" style="height:38.5pt;width:128pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="position:relative;vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:0.1pt;width:0pt;"></div><div style="clear:left;float:left;height:49.5pt;margin-left:9.25pt;margin-right:9pt;width:129pt;z-index:-9223372036603114496;"><div style="height:48.75pt;left:0pt;padding-bottom:0.75pt;position:relative;width:128.65pt;"><img src="plx-20230510xex99d1004.jpg" alt="Graphic" style="height:48.75pt;width:128.65pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#808080;font-family:'Verdana Pro Light';font-size:18pt;">PRESS RELEASE</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-size:14pt;font-weight:bold;">Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of </b><a name="_Hlk129948098"></a><b style="font-family:'Verdana Pro Light';font-size:14pt;font-weight:bold;">ELFABRIO</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Verdana Pro Light';font-size:14pt;font-weight:bold;"> (pegunigalsidase alfa-iwxj) </b><b style="font-family:'Verdana Pro Light';font-size:14pt;font-weight:bold;">for the Treatment of Fabry Disease</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-family:'Verdana Pro Light';font-style:italic;">- PEGylated enzyme replacement therapy designed to provide long half-life* - </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">BOSTON and CARMIEL, Israel, May 10, 2023</b><font style="font-family:'Verdana Pro Light';"> &#8211; Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company</font> <font style="font-family:'Verdana Pro Light';">focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;vertical-align:top;">&#174;</sup><font style="font-family:'Verdana Pro Light';">, announced today that the U.S.&#160;Food and Drug Administration (FDA) has approved ELFABRIO (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">&#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">While much progress has been made in the treatment of Fabry disease, there is still a need for new treatment options,&#8221;</i><font style="font-family:'Verdana Pro Light';"> said </font><b style="font-family:'Verdana Pro Light';font-weight:bold;">Giacomo Chiesi, head of Chiesi Global Rare Diseases</b><font style="font-family:'Verdana Pro Light';">. &#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">We established Chiesi Global Rare Diseases to deliver innovative therapies and solutions for people affected by rare diseases. With the FDA approval of ELFABRIO, we can now offer people living with Fabry disease an alternative treatment option</i><font style="font-family:'Verdana Pro Light';">.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">&#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">We are extremely pleased to receive FDA approval of ELFABRIO for the treatment of adult patients with Fabry disease</i><font style="font-family:'Verdana Pro Light';">,&#8221; said </font><b style="font-family:'Verdana Pro Light';font-weight:bold;">Dror Bashan, Protalix&#39;s President and Chief Executive Officer</b><font style="font-family:'Verdana Pro Light';">. &#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">This approval is a testament to the dedication of the Protalix and Chiesi teams to deliver this much needed new therapeutic option to patients in need. The totality of clinical data suggests that ELFABRIO has the potential to be a long-lasting therapy. Together with Chiesi, we are grateful to all of the patients and investigators and their staff members who participated in our clinical trial programs and remain committed to bringing ELFABRIO to patients with Fabry disease</i><font style="font-family:'Verdana Pro Light';">.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">ELFABRIO is a PEGylated enzyme replacement therapy (ERT). It is a recombinant human &#945;-Galactosidase</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">A enzyme expressed in plant-cell culture that is designed to provide a long half-life.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">The safety, tolerability, and efficacy of ELFABRIO has been studied in a comprehensive clinical development program in more than 140 patients with up to 7.5 years of follow up treatment. It has been studied in both ERT-na&#239;ve and ERT-experienced patients, including a head-to-head trial that met its primary endpoint with ELFABRIO demonstrating non-inferior efficacy to agalsidase beta in controlling estimated glomerular filtration rate (eGFR) decline, and in which ELFABRIO was generally well-tolerated with the majority of adverse events being mild or moderate in severity.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:48.2pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:225.65pt;"></font><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="position:relative;vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:39pt;margin-left:2.0pt;margin-right:9pt;width:128pt;z-index:-9223372036603117568;"><div style="height:38.5pt;left:0pt;padding-bottom:0.5pt;position:relative;width:128pt;"><img src="plx-20230510xex99d1003.jpg" alt="Graphic" style="height:38.5pt;width:128pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="position:relative;vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:0.1pt;width:0pt;"></div><div style="clear:left;float:left;height:49.5pt;margin-left:9.25pt;margin-right:9pt;width:129pt;z-index:-9223372036603116544;"><div style="height:48.75pt;left:0pt;padding-bottom:0.75pt;position:relative;width:128.65pt;"><img src="plx-20230510xex99d1004.jpg" alt="Graphic" style="height:48.75pt;width:128.65pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#808080;font-family:'Verdana Pro Light';font-size:18pt;">PRESS RELEASE</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">&#8220;It is important to understand that there is a lot of variability in Fabry disease and misdiagnoses are common, especially in women,&#8221; said </font><b style="font-family:'Verdana Pro Light';font-weight:bold;">Jack Johnson, founder of the Fabry Support &amp; Information Group (FSIG).</b><font style="font-family:'Verdana Pro Light';"> &#8220;Growing up, a lot of people didn&#8217;t know what was wrong with me. They knew I was different, but they didn&#8217;t know why. Now we have made advances in screening, treatment, and monitoring for Fabry disease.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">*ELFABRIO has an initial half-life of 78.9 &#177; 10.3 hours. Clinical studies have not established that half-life results in superior efficacy or safety based on clinically relevant end points.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-size:18pt;font-weight:bold;">Indication and Important Safety Information</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Indication</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.6;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Elfabrio</font><sup style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:top;">&#174;</sup><font style="font-family:'Verdana Pro Light';"> (pegunigalsidase alfa-iwxj)</font><font style="font-family:'Verdana Pro Light';font-size:13.5pt;"> </font><font style="font-family:'Verdana Pro Light';">is indicated for the treatment of adults with confirmed Fabry disease.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Important Safety Information</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="border-bottom-style:none;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt -4pt 0pt -4pt;padding:1pt 4pt 0pt 4pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS</b></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;padding-left:4pt;padding-right:4pt;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt -4pt 0pt -4pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="border-top-style:none;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;padding-left:4pt;padding-right:4pt;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt -4pt 0pt -4pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Patients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Elfabrio administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue Elfabrio immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Elfabrio may be considered.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Prior to Elfabrio administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and infusion-associated reactions (IARs), and instruct them to seek medical care immediately if such symptoms occur. </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Verdana Pro Light';font-size:11pt;font-style:normal;font-weight:normal;">If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Elfabrio administration and initiate appropriate medical treatment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Verdana Pro Light';font-size:11pt;font-style:normal;font-weight:normal;">If a mild to moderate hypersensitivity reaction or IAR occurs, consider slowing the infusion rate or temporarily withholding the dose.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">In clinical trials, 20 (14%) Elfabrio-treated patients experienced hypersensitivity reactions. </font><font style="font-family:'Verdana Pro Light';"><br></font><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Four Elfabrio-treated patients (3%) experienced anaphylaxis reactions that occurred within 5 to 40 minutes of the start of the initial infusion. The signs and symptoms of hypersensitivity reactions and anaphylaxis included headache, nausea, vomiting, throat tightness, facial and oral edema, truncal rash, tachycardia, hypotension, rigors, </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:48.2pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:225.65pt;"></font><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="position:relative;vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:39pt;margin-left:2.0pt;margin-right:9pt;width:128pt;z-index:-9223372036603117568;"><div style="height:38.5pt;left:0pt;padding-bottom:0.5pt;position:relative;width:128pt;"><img src="plx-20230510xex99d1003.jpg" alt="Graphic" style="height:38.5pt;width:128pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="position:relative;vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:0.1pt;width:0pt;"></div><div style="clear:left;float:left;height:49.5pt;margin-left:9.25pt;margin-right:9pt;width:129pt;z-index:-9223372036603116544;"><div style="height:48.75pt;left:0pt;padding-bottom:0.75pt;position:relative;width:128.65pt;"><img src="plx-20230510xex99d1004.jpg" alt="Graphic" style="height:48.75pt;width:128.65pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#808080;font-family:'Verdana Pro Light';font-size:18pt;">PRESS RELEASE</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">urticaria, intense pruritus, moderate upper airway obstructions, macroglossia, and mild lip edema.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">In clinical trials, 41 (29%) Elfabrio-treated patients experienced one or more infusion-associated reactions, including hypersensitivity, nausea, chills, pruritus, rash, chest pain, dizziness, vomiting, asthenia, pain, sneezing, dyspnea, nasal congestion, throat irritation, abdominal pain, erythema, diarrhea, burning sensation, neuralgia, headache, paresthesia, tremor, agitation, increased body temperature, flushing, bradycardia, myalgia, hypertension, and hypotension. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If glomerulonephritis is suspected, discontinue treatment until a diagnostic evaluation can be conducted.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">When switching to Elfabrio from a prior enzyme replacement therapy, the risk of hypersensitivity reactions and infusion-associated reactions may be increased in certain patients with pre-existing anti-drug antibodies (ADAs). Consider monitoring IgG and IgE ADAs and clinical or pharmacodynamic response (eg, plasma lyso-Gb3 levels).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">The most common adverse reactions (</font><font style="font-family:'Verdana Pro Light';">&#8805;</font><font style="font-family:'Verdana Pro Light';">15%) were</font><font style="font-family:'Verdana Pro Light';"> infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis.</font><font style="font-family:'Verdana Pro Light';"><br><br></font><b style="font-family:'Verdana Pro Light';font-weight:bold;">Please see </b><b style="font-family:'Verdana Pro Light';font-weight:bold;">Full Prescribing Information for Elfabrio</b><b style="font-family:'Verdana Pro Light';font-weight:bold;">.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Fabry Disease</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Fabry disease is an X-linked inherited disease that results from deficient activity of the lysosomal &#945;-Galactosidase</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">A enzyme resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';">) in the lysosomes throughout a person&#8217;s body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the &#945;</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">Galactosidase</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">A enzyme, which is normally responsible for the breakdown of Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';">. The abnormal storage of Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';"> increases with time and, accordingly, Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';"> accumulates, primarily in the blood vessel and tissues. The ultimate consequences of Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';"> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About ELFABRIO</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">ELFABRIO (pegunigalsidase alfa-iwxj), a PEGylated enzyme replacement therapy (ERT) to treat Fabry disease, is a plant cell culture-expressed, and chemically modified stabilized recombinant version of the &#945;</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">Galactosidase</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with stable pharmacokinetic parameters. In clinical studies, ELFABRIO has been observed to have an initial half-life of 78.9 &#177; 10.3 hours. Clinical </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:48.2pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:225.65pt;"></font><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="position:relative;vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:39pt;margin-left:2.0pt;margin-right:9pt;width:128pt;z-index:-9223372036603117568;"><div style="height:38.5pt;left:0pt;padding-bottom:0.5pt;position:relative;width:128pt;"><img src="plx-20230510xex99d1003.jpg" alt="Graphic" style="height:38.5pt;width:128pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="position:relative;vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:0.1pt;width:0pt;"></div><div style="clear:left;float:left;height:49.5pt;margin-left:9.25pt;margin-right:9pt;width:129pt;z-index:-9223372036603116544;"><div style="height:48.75pt;left:0pt;padding-bottom:0.75pt;position:relative;width:128.65pt;"><img src="plx-20230510xex99d1004.jpg" alt="Graphic" style="height:48.75pt;width:128.65pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#808080;font-family:'Verdana Pro Light';font-size:18pt;">PRESS RELEASE</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">studies have not established that half-life results in superior efficacy or safety based on clinically relevant end points.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Chiesi Global Rare Diseases</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">For more information visit </font><font style="font-family:'Verdana Pro Light';">www.chiesirarediseases.com</font><font style="font-family:'Verdana Pro Light';">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Chiesi Group</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company&#8217;s mission is to improve people&#8217;s quality of life and act responsibly towards both the community and the environment. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi&#8217;s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we&#8217;re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group&#8217;s research and development centre in Parma works alongside 6 other important R&amp;D hubs in France, the US, Canada, China, the UK, and Sweden.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">For further information please visit </font><font style="font-family:'Verdana Pro Light';">www.chiesi.com</font><font style="font-family:'Verdana Pro Light';">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#0563c1;font-family:'Verdana Pro Light';text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Protalix&#8217;s first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:48.2pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:225.65pt;"></font><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="position:relative;vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:39pt;margin-left:2.0pt;margin-right:9pt;width:128pt;z-index:-9223372036603117568;"><div style="height:38.5pt;left:0pt;padding-bottom:0.5pt;position:relative;width:128pt;"><img src="plx-20230510xex99d1003.jpg" alt="Graphic" style="height:38.5pt;width:128pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="position:relative;vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:0.1pt;width:0pt;"></div><div style="clear:left;float:left;height:49.5pt;margin-left:9.25pt;margin-right:9pt;width:129pt;z-index:-9223372036603116544;"><div style="height:48.75pt;left:0pt;padding-bottom:0.75pt;position:relative;width:128.65pt;"><img src="plx-20230510xex99d1004.jpg" alt="Graphic" style="height:48.75pt;width:128.65pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#808080;font-family:'Verdana Pro Light';font-size:18pt;">PRESS RELEASE</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945;-Galactosidase-A protein for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa-iwxj.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Protalix&#8217;s Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on Protalix&#8217;s current beliefs and expectations as to such future outcomes. Factors that might cause material differences include, among others: risks related to the commercialization of ELFABRIO; the likelihood that the FDA, European Medicines Agency (EMA) or other applicable health regulatory authorities will approve an alternative dosing regimen for ELFABRIO; risks related to the commercial success of Protalix&#8217;s other product and product candidates, if approved; failure or delay in the commencement or completion of preclinical studies and clinical trials of our other product candidates which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:48.2pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:225.65pt;"></font><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="position:relative;vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:39pt;margin-left:2.0pt;margin-right:9pt;width:128pt;z-index:-9223372036603117568;"><div style="height:38.5pt;left:0pt;padding-bottom:0.5pt;position:relative;width:128pt;"><img src="plx-20230510xex99d1003.jpg" alt="Graphic" style="height:38.5pt;width:128pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="position:relative;vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:0.1pt;width:0pt;"></div><div style="clear:left;float:left;height:49.5pt;margin-left:9.25pt;margin-right:9pt;width:129pt;z-index:-9223372036603116544;"><div style="height:48.75pt;left:0pt;padding-bottom:0.75pt;position:relative;width:128.65pt;"><img src="plx-20230510xex99d1004.jpg" alt="Graphic" style="height:48.75pt;width:128.65pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#808080;font-family:'Verdana Pro Light';font-size:18pt;">PRESS RELEASE</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Chiesi Group Media Contact</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Chiara Travagin</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Verdana Pro Light';font-style:italic;">Rare Communication Manager</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Tel: +39 348 8818985</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';white-space:pre-wrap;">Email  </font><font style="font-family:'Verdana Pro Light';">c.travagin@chiesi.com</font><font style="font-family:'Verdana Pro Light';"> </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Alessio Pappagallo</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Verdana Pro Light';font-style:italic;">Press Office Manager</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Tel: +39 339 5897483</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Email </font><font style="font-family:'Verdana Pro Light';">a.pappagallo@chiesi.com</font><font style="font-family:'Verdana Pro Light';"> </font><u style="color:#0563c1;font-family:'Verdana Pro Light';text-decoration-color:#0563c1;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Adam Daley</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Verdana Pro Light';font-style:italic;">Berry &amp; Company Public Relations</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">1-212-253-8881</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">adaley@berrypr.com</font><font style="font-family:'Verdana Pro Light';"> </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Protalix Investor Contact</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Chuck Padala, Managing Director</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Verdana Pro Light';font-style:italic;">LifeSci Advisors</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">646-627-8390</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Verdana Pro Light';">chuck@lifesciadvisors.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20230510xex99d1003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230510xex99d1003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T *L# 2(  A$! Q$!_\0
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M@F]^R5;Q^,?C5\<?'FH#SM6&O-HELTG+6]M%G"#T!"Q_]\4 :=C^S7\4O%L
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M?Q;^)-AK2C9+X8FU>;^UDN/^> MA'O9\\# *GKG'- 'L?CG]HO1/"GPO\/\
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M+6[^(/@+_A&_#=S-' VM:=JJ:A%8L[!4^U*$1D0L0#(NY02,X'-=-\1?BO\
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M,#% ';A%!S@9]<4AB4G)Y-%% "3V\=S$T4J++&PPR. P/U!IT<:Q(J(H1%&
MJC  HHH  @!) Y/6@(%! XS110 *@4\<5&;2$W G,2>>!M$NT;@/3/6BB@"1
MD#')YHV\#KQ110!%%9P0&0Q0QQ&0Y<H@&X^_K7D7CQ0O[37PF Z#2M<_]!M:
M** /7H+."V+F&)(BYR_EJ%W'U..M2LH=2K %2,$'O110!';VT5I&(X(DAC'.
MR-0H_(47%K%=QF.:-)8SU210P/X&BB@!ZQJF-H P,# Z#TH$:KNP.&ZBBB@
M"!5P.![5%%900-(T4,<32'+E%"EC[XZT44 /EMXY]OF1K)M.1N4'!]>:>!@4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20230510xex99d1004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230510xex99d1004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B 0(# 2(  A$! Q$!_\0
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MSW\O'H37DQ_X+F'S\CX,?N?0^)_F_/[)_2O/_P#@G/\ \$Z_"W[0O@JX\?\
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M)%C!?'H55J^]A_P5"_9D(S_PLU?_  1ZE_\ (U(Q/IK6=5@T'1[[4KHD6UG
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M'B&SCDV3:W<V^G@ X)7=YC?^@#\Z^P*_,#_@MGXU\CPUX \+))S//-?2(#V
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MFO>&=:T=X;348YDM=0N6_BL\D[NHR5R<#ODU]%^%O#5AX.\.:=H>EQ>1I]A
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M3CL:]5USXB>.O%7Q-USPEX%'AW3DT&WADO;W7UFF>>65=R)'%&RX0#JY)YZ
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MD\6_ [6-7BM)+*&[^)D4L<4J;&VF_7!([9'/XU[C\0?"WPO^*GC#4(D\5?\
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G7;+F&.X3?C;*H8?K7N]M#'! B1(L: <*@P!^%%%)"1+1113&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20230510.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2023 10:18:07 AM-->
<!--Modified on: 5/10/2023 10:18:07 AM-->
<xsd:schema targetNamespace="http://protalix.com/20230510" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://protalix.com/20230510" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20230510_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2023 10:18:07 AM-->
<!--Modified on: 5/10/2023 10:18:07 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20230510.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20230510_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2023 10:18:07 AM-->
<!--Modified on: 5/10/2023 10:18:07 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20230510.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20230510.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638193106876444836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638193106876444836" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638193106876444836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638193106876444836" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638193106876444836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638193106876444836" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638193106876454833" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638193106876454833" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638193106876454833" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638193106876454833" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638193106876454833" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638193106876454833" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638193106876454833" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638193106876454833" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638193106876454833" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638193106876454833" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638193106876454833" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638193106876454833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638193106876454833" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638193106876464835" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638193106876464835" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638193106876464835" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638193106876464835" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638193106876464835" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638193106876464835" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638193106876464835" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638193106876464835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638193106876464835" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140211390092624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>plx-20230510x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20230510.xsd" xlink:type="simple"/>
    <context id="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-05-10</startDate>
            <endDate>2023-05-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_51Z7Tx_vFUW1pZuosJDL-w_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_NbsMITndokKPDD3nzkBKGg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_Umhr-8V7EUS155CB_EeG2w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_qvhVZlugAEu2uqv3hRDAEA">2023-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_J0KFKz5yNESsTltE7q7WjA">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_6syoK3mXA0KLPwtgHn-VwA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_R2KzHtJ0ykKecPFIsPhIyA_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_8q0YhGrLREm2jPzp2BA5Qg_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_qCreB7x6XUGTyDg3vSOI6Q_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_MkBngZ3O-kWclAdz8e1NMw_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_64LjIYpPBkGZyBRZOA6fGw">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_Z_NYv0CilEaCddyJryq9bQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_dlRLqiCO3UCsHBp-pnkwWA_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_ylZ6-Xmtd0ugBU5ywMHSmg">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_JjM93AW0GEOgTNW4AcWxvg">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_Mt4HiR-DoUmxn3EUz-a1og">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_VlUf7qNlfU-hZmvZwmHH2g">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_ry6IU21oP0utXATPzFW4gA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr_n4QYc1-AR0WwqNO1qBpVtw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_L_t2sNxTCEi-OVboTCla7w_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_Rl35CkyOoUSFsAPXjCRR-Q_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Tc_Bukrt2ZW50SdEPcWo3D54g_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A"
      id="Narr__oUd76jhxk6t1IBHLOwvbw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M='@//GL?)=-[*CG_5U/\!%!+ P04    "  Q,ZI6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( #$SJE8<.&7J/P$
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M?P%02P$"% ,4    "  Q,ZI6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #$SJE:_W2^?[P   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( #$SJE:97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ ,3.J5N9D9)5H!   51$  !@
M         ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( #$SJE:?H!OPL0(  .(,   -              "  :P,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ ,3.J5I>*NQS     $P(   L
M ( !B \  %]R96QS+RYR96QS4$L! A0#%     @ ,3.J5APX9>H_ 0  / (
M  \              ( !<1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M #$SJE8D'INBK0   /@!   :              "  =T1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #$SJE9ED'F2&0$  ,\#   3
M              "  <(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(   P4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20230510x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20230510x8k.htm">plx-20230510x8k.htm</File>
    <File>plx-20230510.xsd</File>
    <File>plx-20230510_lab.xml</File>
    <File>plx-20230510_pre.xml</File>
    <File>plx-20230510xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20230510x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20230510x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20230510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20230510_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20230510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20230510",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230510x8k.htm",
      "contextRef": "Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230510x8k.htm",
      "contextRef": "Duration_5_10_2023_To_5_10_2023_-iovroYt-0a2PulknYQD0A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20230510",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-008953-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-008953-xbrl.zip
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M#KE];8#>BZM(%L2/XOIQ\3LRH[FMLQY*0[0BCB61U2"::CT1P=P64E\0QC7
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M=-5AHU9)_VHGEV8B%-2R37];BS=!YQ:^PQ]DF!@WQT^!K1\>2C\%<GX!Y3J
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M%.X7E]T'/< &$8I354-*^ P7",:*.'<MPLY3UJ(K,Q-@+'(YU+=BG@1;Y9[
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MGS]+ZQ*MW*7<Y)%(D:+L0R85XC/]$LY,EF+;*3=4SSG%BG?D$G4^5JFU0ZY
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M^F0KKPU@RB@595K2B]L:_WN,%6X15489([!WE)VRO,;Y $;)K7(G\H<VC9T
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M'$/')N@6'PY%AC8%ZFI;@97@@O@G2#PP,W5(+\RLP8<Y3_8 J"<R\-EL!>Z
MF#LFXV 0-!:#%>.OYYC?Y[*-@;L:&H$Q*".OL#A@]C4$$=6Z!RLMQ^&:NE(I
MR2J?90*YE?(5RC==;XZB1W,'._@3%8K(W4&_RMA;I\OE@RA5L1KC=[ X=ELM
M^,H3?TW(P;PJD>+)+99^5VF:EM7MC&E5 RNY&B!- Z1I@#0-:F.%41O-EJS<
MEC1 F@9(TP!I&B#-$PA:-T":!DBSLF3: &F:&3= F@9(L[) &N\*=]<R.J3,
M@@.J<C*G MW(B*&16(K)WDB%EC\?BWJ4TL4]T"V*%\S9;$'T(8XDA@!J994^
M=LXZ/_W0V^D.:L%@;.CH@DI&"': E1V,O5OW?#[Z=W5X>P*KBL&_F&H].#<?
M.F\9^@[)61^BQP_O6T5/,#GOU3#V,6@LVY31\]1!+36:DO4$\"@OK^#4L(;D
M_1W.6,RG#83C7K6G[H/JF*MSAJ%0CE>:YD"-7QG$<<])<,W9N>83#DU^Y9'+
M6XV<GNU+C.(&\#95;CNP)4UL%(R]HQB$?KDN5Y4AGOUR+N(^^^_-/;:YM<MV
M=WN[>[O;J\W$TTCFHFTR'H@^7N^+3A=HXRCA,F9W+-@0=')'<O^Z;]V&%2\:
M<XGI5@K6ULQD]69RKYH8,54^8"<\RSA6FE+?DT@_(=OJ X;&Q7<FS.%_V[M[
M+[9V-U>;]+W<OINLY9VL)*R'$]S%PO'OCC5PYM^^1X4<&EJQ:F515TA>/:I=
MO1_RA!WR6,R^?<GF>TFS5T+#X97JD:&=2L5P3@HX]P7LU"-D'EVZ/7!5ZEY[
MH[?1WMC>;.^"[;H2M'9;)P12UK^&N#>97G&K\T'G_I1E1IF <TP 3P01?J6C
M^".[&(K@$]AR0+.\90TBQ&$=2BW0Y_7M)W<O^?A6CL19(-E^"*2I]'<G"W>V
M=MH[&R_:NYM[W54W^@*DI']A]6(32.X6O"[]OB:F[_X OHF2X4WXO?6A"F?P
M3Y0G\2__#U!+ 0(4 Q0    ( #$SJE;AZABLN ,  ,X,   0
M  "  0    !P;'@M,C R,S U,3 N>'-D4$L! A0#%     @ ,3.J5M=\OM::
M!0  X3X  !0              ( !Y@,  '!L>"TR,#(S,#4Q,%]L86(N>&UL
M4$L! A0#%     @ ,3.J5DAQR8^3!   0BH  !0              ( !L@D
M '!L>"TR,#(S,#4Q,%]P<F4N>&UL4$L! A0#%     @ ,3.J5ED>16I#%
M')4  !,              ( !=PX  '!L>"TR,#(S,#4Q,'@X:RYH=&U02P$"
M% ,4    "  Q,ZI6@-WU-"DB  "F!@$ %P              @ 'K(@  <&QX
J+3(P,C,P-3$P>&5X.3ED,2YH=&U02P4&      4 !0!( 0  244

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
